News & Updates

Subcutaneous (SC) semaglutide 2.4 mg QW is recently granted accelerated approval by the US FDA for treatment of metabolic dysfunction–associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis.

Many paediatric sexual assault victims do not receive hepatitis B virus (HBV) postexposure vaccination and have low compliance to HIV postexposure prophylaxis (PEP), reveals a study in Singapore.

Nearly one in five hepatitis C virus (HCV) infections in the last decade have been treated with direct-acting antivirals (DAAs), as well as about a third of the target population, according to a study.